EOX regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
EOX regimen refers to a regimen consisting of epirubicin, oxaliplatin, capecitabine (xeloda) used to treat advanced oesophagogastric cancer.[1]
Regimen
EEpirubicin
OOxaliplatin
XCapecitabine (xeloda)
Indications
References
- ↑ 1.0 1.1 Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR; et al. (2005). “Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF”. Br J Cancer. 92 (11): 1976–83. doi:10.1038/sj.bjc.6602572. PMC 2361798. PMID 15928658.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH